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AdjuvantInfluenza A virus (IAV) causes a disease burden in the swine industry in the US and is a challenge to pre-
vent due to substantial genetic and antigenic diversity of IAV that circulate in pig populations. Whole
inactivated virus (WIV) vaccines formulated with oil-in-water (OW) adjuvant are commonly used in
swine. However, WIV-OW are associated with vaccine-associated enhanced respiratory disease
(VAERD) when the hemagglutinin and neuraminidase of the vaccine strain are mismatched with the chal-
lenge virus. Here, we assessed if different types of adjuvant in WIV vaccine formulations impacted VAERD
outcome. WIV vaccines with a swine d1-H1N2 were formulated with different commercial adjuvants:
OW1, OW2, nano-emulsion squalene-based (NE) and gel polymer (GP). Pigs were vaccinated twice by
the intramuscular route, 3 weeks apart, then challenged with an H1N1pdm09 three weeks post-boost
and necropsied at 5 days post infection. All WIV vaccines elicited antibodies detected using the hemag-
glutination inhibition (HI) assay against the homologous vaccine virus, but not against the heterologous
challenge virus; in contrast, all vaccinated groups had cross-reactive IgG antibody and IFN-c responses
against H1N1pdm09, with a higher magnitude observed in OW groups. Both OW groups demonstrated
robust homologous HI titers and cross-reactivity against heterologous H1 viruses in the same genetic lin-
eage. However, both OW groups had severe immunopathology consistent with VAERD after challenge
when compared to NE, GP, and non-vaccinated challenge controls. None of the WIV formulations pro-
tected pigs from heterologous virus replication in the lungs or nasal cavity. Thus, although the type of
adjuvant in the WIV formulation played a significant role in the magnitude of immune response to
homologous and antigenically similar H1, none tested here increased the breadth of protection against
the antigenically-distinct challenge virus, and some impacted immunopathology after challenge.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).1. Introduction Vaccine protection against this vast antigenic diversity of IAVInfluenza A viruses (IAV) of H1 and H3 subtypes are shared
between humans and pigs, and swine-adapted IAV occasionally
cause zoonotic infections of public health concern. Periodic spil-
lovers of human seasonal IAV to swine significantly contributed
to the genetic and antigenic diversity of IAV in U.S. swine popula-
tions [1–3]. After the emergence of the pandemic H1N1
(H1N1pdm09) in humans [4], repeated transmission from humans
to swine occurred globally, highlighting the role of reverse zoono-
sis [5] and further increasing the diversity of IAV in swine [2].[2,3,6] in the U.S. swine population is a challenge since strains
are not systematically updated as undertaken through the human
IAV vaccine strain selection system. Although new IAV vaccine
platforms are licensed for use in swine [7,8] commercial whole-
inactivated virus (WIV) vaccines formulated with oil in water
(OW) adjuvant are the most commonly used vaccine to control
IAV in swine [9]. WIV vaccines induce protective immune
responses against homologous and antigenically-related IAV
strains; however, cross-protection against heterologous IAV can
be limited and cross-reactive immune responses have been associ-
ated with enhanced lung pathology [10]. A model of vaccine asso-
ciated enhanced respiratory disease (VAERD) has been reported
when pigs are vaccinated with a monovalent WIV followed by a
heterologous challenge containing the same hemagglutinin (HA)
6104 C.K. Souza et al. / Vaccine 36 (2018) 6103–6110subtype. This model has been experimentally reproduced with sev-
eral IAV strain combinations and with pigs at different ages at vac-
cination and challenge [11–16]. The outcome is severe disease
characterized by prolonged fever with severe bronchointerstitial
pneumonia, necrotizing bronchiolitis, and peribronchiolar lympho-
cytic cuffing [11,12]. Although the mechanisms responsible for
VAERD are not completely understood, non-neutralizing IgG anti-
bodies were shown to be targeted to a conserved region of the
HA2 stalk close to the fusion peptide domain of the heterologous
HA, and led to enhanced virus infectivity by promoting virus
membrane fusion activity [17]. In addition, pro-inflammatory and
anti-viral cytokine dysregulation were associated with the severe
lung pathology and may contribute to neutrophil infiltration into
the lungs [13]. An HA subunit vaccine formulated with OW adju-
vant followed by a mismatched challenge also resulted in VAERD
[15]. However, immunity to the neuraminidase (NA) protein also
played an important role in abrogating VAERD when the NA of
the vaccine and challenge strains were matched [14]. In contrast,
age of vaccination and timing of challenge did not alter the VAERD
outcome in growing pigs [16].
Adjuvants are widely used in vaccine formulations to modulate
antigen-specific immunity by magnifying or shaping T-helper
immune responses [18,19]. The humoral response against IAV pro-
vides protection through specific neutralizing antibodies to the HA
[20], and cell-mediated immunity (CMI) also play a role in aug-
menting the B-cell response and providing partial protection
against heterologous or heterosubtypic IAV strains [21,22]. There
is a need to develop IAV vaccines for pigs that confer cross-
protection against heterologous infection without resulting in
VAERD. Although VAERD was associated with the use of WIV-OW
vaccination, it was unknown if the type of adjuvant in the WIV for-
mulation would impact the immunopathology of VAERD. Here, we
demonstrate that the type of adjuvant in the WIV vaccine formula-
tion impacted the magnitude of immune response and subsequent
degree of immunopathology after heterologous challenge high-
lighting the role of the adjuvant component on the spectrum of
quality and quantity of immunity.2. Material and methods
2.1. Viruses and vaccine formulations
The vaccine virus, A/sw/MN/02011/08 H1N2 (d1-H1N2), was
grown in Madin-Darby canine kidney (MDCK) cells with OptiMEM
(Gibco, Thermo Scientific, USA) and was inactivated and prepared
as previously described [23]. Four commercial adjuvants, OW1,
OW2, nano-emulsion (NE) and gel polymer (GP), were used toTable 1
Study design and adjuvant properties.
WIV
group
N Vaccination
(4 wk)
Boost
(7 wk)
Adjuvant Major immunostim
component§
*OW1 10 d1-H1N2 d1-H1N2 Emulsigen-D TM MVP Oil in water (OW)
*OW2 10 d1-H1N2 d1-H1N2 Seppic MONTANIDETM
ISA 15A VG
Mineral OW based
*NE 10 d1-H1N2 d1-H1N2 Invivogen AddaVaxTM Squalene-based n
(similar to MF59)
*GP 10 d1-H1N2 d1-H1N2 Seppic MONTANIDETM
Gel 01
Sodium polyacryla
water
*NV/C 10 – – –
NV/NC 5 – – –
IM: intramuscular route.
§ Information from manufacturer’s label. The proportion of adjuvant and the route of a
* All WIV groups and NV/C were challenged with H1N1pdm09 strain at 10 weeks of agformulate WIV vaccines according to the manufacturer’s recom-
mendations (Table 1).
2.2. Experimental design
At three weeks of age, pigs were obtained from a herd free from
IAV and porcine reproductive and respiratory syndrome virus
(PRRSV) and treated prophylactically with ceftiofur (Zoetis,
Parsippany, NJ) according to label directions to reduce potential
bacterial respiratory pathogens. Prior to vaccination, pigs were
screened for antibody against IAV nucleoprotein (NP) by ELISA
(MultiS ELISA, IDEXX, Westbrook, Maine, USA) to ensure the
absence of preexisting antibodies against IAV. Pigs were housed
in biosafety level 2 (BSL2) containment during the vaccination
and challenge phases of the study and cared for in compliance with
the Institutional Animal Care and Use Committee (IACUC) of the
National Animal Disease Center (NADC).
Pigs were vaccinated with 2 mL of the assigned WIV, by the
intramuscular route, as described in Table 1 and challenged with
105 50% tissue culture infectious dose (TCID50) per mL of
A/CA/04/2009 (H1N1pdm09), with 2 mL instilled in the trachea
and 1 mL instilled in the nose [24]. Nasal swabs were collected at
0, 1, 3, and 5 days post infection (dpi). At 5 dpi, pigs were humanely
euthanized with a lethal dose of pentobarbital (FatalPlus, Vortech,
Dearborn, MI, USA). Rectal temperatures were recorded daily until
necropsy. Broncho-alveolar fluid (BALF) samples were collected at
necropsy, as previously described [14].
2.3. Macroscopic and microscopic lung lesions
Lungs were removed at necropsy and the percentage of the sur-
face area affected with pneumonia was visually estimated as pre-
viously described [12]. Tissue samples from the trachea and the
right middle or affected lung lobe were fixed in 10% buffered for-
malin for histopathologic examination. Slides were stained with
hematoxylin and eosin (H&E) or immunohistochemistry (IHC)
and evaluated by a veterinary pathologist blinded to the treatment
groups [12].
2.4. Virus titration
Nasal swabs and BALF samples were used for virus titration on
MDCK cells, as previously described [25]. MDCK-inoculated
monolayers were evaluated for cytopathic effect (CPE) at 48 h
post-infection and subsequently fixed with 4% phosphate-
buffered formalin and stained using immunocytochemistry (ICC)
with anti-influenza A nucleoprotein monoclonal antibody [26]. A
TCID50 titer was calculated for each sample [27].ulatory (v/v) Route Type of immune response
emulsion 20% IM Humoral response (strong short-term
immunity)
emulsion 15% IM Humoral response (strong short-term
immunity)
ano-emulsion 50% IM Humoral and/or cellular responses.
Cytokines and chemokines
te polymer in 10% IM Humoral and/or cellular responses.
Cytokines and chemokines
– – –
– – –
dministration were performed following the manufacture recommendations.
e.
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Serum samples collected prior to vaccination, pre-challenge
(42 days post vaccination-dpv or dpi 0) and dpi 5 were heat inac-
tivated at 56 C for 30 min and hemagglutination inhibition (HI)
assays were conducted against the homologous vaccine virus
(d1-H1N2) and heterologous challenge virus (H1N1pdm09), using
turkey red blood cells, as described [28]. HI titers were divided
by 10 and log2 transformed, analyzed, and reported as the geomet-
ric mean titer (GMT) [27]. Pre-challenge sera were also evaluated
by HI assays using genetically-related but heterologous H1 strains
listed in Supplementary material 1 and 2.
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.vaccine.2018.08.
072.
Independent ELISAs were conducted using whole virus prepara-
tions to detect IgA and IgG antibody specific to d1-H1N2 and
H1N1pdm09 following a described protocol [29]. ELISA results
were reported as mean OD for each duplicate sample and the mean
of each group was compared.
2.6. Neuraminidase inhibition assay
Neuraminidase specific antibodies were measured in post boost
(dpi 0) sera by neuraminidase inhibition (NI) assays. Antigens were
viruses with homologous NA of d1-H1N2 (homologous N2-98), a
drifted N2-98 (A/swine/Texas/4199-2/1998) within the swine
1998-lineage, or a heterologous N2-02 (A/turkey/
Ohio/313053/2004) from the swine 2002 N2 lineage, each paired
with an HA gene from an unrelated strain (A/guinea fowl/HK/
WF10/1999 H9N2) [30]. NI titer of each serum sample was defined
as the highest dilution that resulted in 50% inhibition of NA activity
[30].
2.7. Interferon-c ELISpot assay
Peripheral blood mononuclear cells (PBMC) were collected at
28 days post vaccination (dpv; or 1 week post-boost) and at 42
dpv (or pre-challenge) and stimulated with homologous (d1-
H1N2) and heterologous (H1N1pdm09) strains, positive control
(Pokeweed mitogen) or media (sham) to evaluate the number of
interferon-gamma secreting cells (IFN-c SCs) in an ELISpot assay
(porcine IFN-c ELISpot assay, R&D systems, Minneapolis, MN),
using a previously described protocol [31]. Plates were scanned
and spots enumerated using CTL-ImmunoSpot S5 UV Analyzer
and ImmunoSpot 5 Software. The reported values were calculated
from the average number of spots counted for duplicate wells
receiving virus, subtracted by the number of spots in the mock
stimulated wells.
2.8. Antigenic cartography and antibody landscaping
HI data (Supplementary material 1) were used to create 2
dimensional (2D) antigenic maps to quantify the inter-
relationships among delta (1B.2)-lineage strains (Supplementary
material 2) using antigenic cartography [6,32]. Antibody land-
scapes were generated as previously described using RStudio
1.0.44 [33]. The HI titers were plotted in the 3rd dimension as a
smooth landscape over the 2D antigenic maps (Supplementary
material 3). Since the minimum dilution used in the HI assays
was 1:10, undetectable titers were given a set value of 10. The
distance between the viruses in the x- and y-axis represent anti-
genic distance while the height of the landscape (z-coordinate)
represent antibody titers (geometric mean value) to the respective
virus strains. The antibody landscapes visualize the breadth of
antibody response of each WIV-adjuvant group against H1 strains.The colors used for strains in the antibody landscaping were based
on genetic lineage, as previously described [34].2.9. Statistical analysis
Lung lesions scores, log10 transformed virus titers, log2 HI titers,
mean OD ELISA IgA and IgG antibody levels and number of IFN-c
SC were analyzed using analysis of variance (ANOVA) with a p
value  0.05 considered significant (Graph Pad Prism Version
5.00, San Diego, CA). Response variables shown to have significant
differences among groups were subjected to pair-wise comparison
using the Tukey-Kramer test.3. Results
3.1. OW vaccinated pigs with heterologous challenge resulted in
VAERD
All pigs were negative for IAV NP-specific antibodies prior to
vaccination. BALF samples were negative for PCV2, M. hyopneumo-
niae and PRRSV and aerobic bacterial pathogens were not detected.
Upon heterologous infection, OW-vaccinates demonstrated clinical
signs such as coughing and increased respiratory effort, consistent
with previous findings in other VAERD studies. In contrast, NE and
GP groups demonstrated only mild signs of respiratory disease
after challenge. OW1 pigs demonstrated febrile responses, as
defined as from 2 to 5 dpi and were significantly higher than NV/
NC controls, OW2 pigs were febrile at 2 and 3 dpi, and the NE pigs
were febrile at 3 dpi (data not shown).
OW1 (22.1%) and OW2 (21.7%) had significantly higher group
mean percentages of macroscopic lung lesions when compared to
NE (11.3%) and GP (9.3%) which were more similar to NV/C controls
(6.1%) (Fig. 1A). OW1 (14.4) and OW2 (14.6) presented significantly
higher microscopic lung lesions scores compared to GP (7.8) and
NV/C control (5.1) (Fig. 1B). OW1 (5.6) had a mean microscopic tra-
chea lesions score that was significantly higher compared to other
adjuvant and control groups (Fig. 1C). IAV antigen detection was
confirmed in the lungs and trachea in all vaccinated groups by
IHC, but mean scores were not statistically different between
groups.3.2. Virus shedding and replication in the lungs
All groups were negative for IAV in nasal swabs pre-challenge.
NE and GP groups shed virus at low titers at 1 dpi (data not shown).
At 3 and 5 dpi, all WIV groups shed H1N1pdm09 at titers similar to
NV/C (Fig. 1D and E). In addition, all vaccinated groups demon-
strated high virus titers in the lungs (Fig. 1F).3.3. Peripheral and local antibody responses
All WIV groups demonstrated HI titers against the homologous
d1-H1N2 vaccine strain at 0 (Fig. 2A) and 5 dpi (Fig. 2B), with high-
est pre-challenge titers in the OW1 and OW2 groups. However,
none of the vaccinated groups elicited detectable HI titers to the
heterologous challenge strain (H1N1pdm09, data not shown).
OW1 and OW2 showed significantly higher anti-d1-H1N2 and
cross-reactive anti-H1N1pdm09 IgG levels compared to other vac-
cinated groups and controls at 0 and 5 dpi (Fig. 2C–F).
All vaccinated groups showed similar levels of anti-d1-H1N2
IgA in BALF. However, no cross-reactive anti-H1N1pdm09 IgA
responses were observed (Fig. 2G and H). In contrast, all vaccinated
groups demonstrated significantly higher levels of anti-d1-H1N2
and cross-reactive anti-H1N1pdm09 IgG responses in BALF
Fig. 1. Percentage of lung lesions of WIV-1d-H1N2 vaccinated groups followed by a heterologous challenge (H1N1pdm09) and virus titers in nasal swab and lungs. OW1 and
OW2 vaccinated pigs presented significantly higher percentage of lung lesions consistent with VAERD when compared with other adjuvants and controls (A). Group mean
microscopic scores are significantly higher in OW groups in lungs (B) and trachea (C) compared to NV/C controls. Virus titers (Log10 TCID50) of vaccinated/challenge pigs
compared with controls (NV/C) in nasal swabs at 3 (D) and 5 (E) dpi and virus titers in the lungs (F). Treatment group means with statistically significant differences (P  0.05)
are identified by different lowercase letters.
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levels (Fig. 2I and J).3.4. OW adjuvants elicited a broader antibody response against HA
and NA
All vaccinated groups presented NI antibodies against the
homologous antigen of the N2-98 genetic lineage, and both OW
groups had significant cross-reactivity against the drifted N2-98
antigen compared to other adjuvants (Fig. 3A and B). However,
no cross-reactivity was found against the heterologous N2-02 lin-
eage antigen, regardless of the adjuvant type (Fig. 3C).
The breadth and magnitude of response between both OW
adjuvants showed a similar range among genetically-related H1
d-lineage strains in the antibody landscapes (Fig. 4A). In contrast,
NE and GP landscapes demonstrated a more restricted span among
H1 d-lineage strains compared to the OW1 landscape (Fig. 4B and
C). In accordance with the HI results (Supplementary material 1),
the maximum height for each landscape corresponded to the anti-
body titer to the vaccine strain (d1-H1N2), with the OW adjuvants
stimulating higher homologous titers. None of the landscapes
spanned over H1N1pdm09.3.5. IFN-c recall responses to d1-H1N2 and H1N1pdm09 following
vaccination
All WIV groups (OW1, OW2, NE and GP) showed significantly
higher group mean numbers of IFN-c secreting cells compared to
NV controls at 28 dpv (61, 132, 80 and 26, respectively) and at
pre-challenge (42 dpv) (33, 80, 36 and 35, respectively) against
vaccine antigen d1-H1N2 (Fig. 5A) and challenge antigen
H1N1pdm09-specific at 28 dpv (51, 146, 39 and 29, respectively)and at 42 dpv (36, 88, 39 and 29, respectively) when compared
to controls (Fig. 5B).4. Discussion
Adjuvants can modulate antibody and cell-mediated adaptive
immune responses, allow for the use of smaller doses of antigen,
or may reduce the number of administrations required to achieve
protection [35]. OW emulsions are broadly used in veterinary vac-
cines to improve immunogenicity and elicit potent immune
responses [36], so two commercial sources of OW were tested in
our study. The other two adjuvants selected were a squalene-
based nano-emulsion adjuvant (NE) similar to MF59 formulation
that is licensed for adjuvanted influenza vaccines for humans
[37,38], and a stable dispersion of high molecular weight sodium
polyacrylic gel polymer particles in water adjuvant (GP) reported
to induce a balanced Th1/Th2 immune response [39,40].
WIV-OW vaccines have been associated with enhanced respira-
tory disease in pigs. VAERD has been reproduced in pigs using mul-
tiple combinations of IAV vaccines followed by a mismatched
challenge strain [10,13–16,41], but only in the context of OW adju-
vanted vaccines. Here, we demonstrated that the type of adjuvant
did indeed impact the development of VAERD in this model. Both
OW vaccinated groups demonstrated severe lung pathology con-
sistent with previous VAERD studies [11,12,16], in contrast to
other adjuvants (NE and GP) that showed mild lung lesions, similar
to the non-vaccinated/infected controls. However, none of the WIV
formulations protected pigs from virus infection with the mis-
matched H1N1pdm09.
Although, all vaccinated groups demonstrated IgA against the
homologous vaccine strain (d1-H1N2), no cross-reactive IgA muco-
sal responses to H1N1pdm09 were detected in the lungs, as
Fig. 2. Peripheral and local immune responses against the vaccine (d1-H1N2) and challenge (H1N1pdm09) strains. Hemagglutination Inhibition (HI) geometric mean titer
(Log2) against the vaccine strain (d1-H1N2) at 0 dpi (A) and 5 dpi (B). ELISA optical density (O.D.) of IgG anti-d1-H1N2 at 0 dpi (C) and 5 dpi (D). Cross-reactive anti-
H1N1pdm09 at dpi 0 (E) and dpi 5 (F) were significantly higher in both OW than other groups. Lung IgA responses against the vaccine (d1-H1N2) (G) and challenge strains
(H1N1pdm09) (H). Lung IgG anti-d1-H1N2 (I) and cross-reactive anti-H1N1pdm09 (J) were significantly higher in both OW than other groups. Treatment group means with
statistically significant differences (P  0.05) are identified by different lowercase letters.
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Fig. 3. Serum NI antibody responses to WIV containing d1-H1N2 strain formulated with different adjuvants (OW1, OW2, NE and GP). All vaccinated groups demonstrated NI
antibody response against homologous N2 (d1-H1N2) (A). (B) NI antibody response against a drifted N2 within the same 1998-lineage of d1-H1N2 was significantly higher in
both OW groups. (C) None of the groups presented NI antibody response against heterologous N2, representing the 2002-lineage. Treatment group means with statistically
significant differences (P  0.05) are identified by different lowercase letters.
Fig. 4. Antibody landscaping representing the serological data from the vaccination
of swine with WIV formulated with OW1 adjuvant (red) compared with the other
adjuvants (green) (A) OW1 vs OW2. (B) OW1 vs GP. (C) OW1 vs NE. Swine d1-H1N2
strains are colored in yellow, swine d2-H1N2 in brown, human strains in grey,
pandemic H1N1 2009 strain in red and vaccine strain (A/H1N2/Swine/Minnesota/
02011/2008) in black. OW1was chosen as a control adjuvant to compare with other
landscapes. The landscape for OW1 was colored red, while OW2, NE and GP
landscapes were colored green. Z axis represents the geometric mean of the HI
titers at each antigenic point for each swine population. The x and y axis represent
the coordinates of the virus strains derived from the 2D antigenic map.
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H1N1pdm09 cross-reactive IgG responses in serum and lungs,
however OW groups demonstrated greater magnitude of cross-
reactive IgG antibody response, in association with the observed
immunopathology. Non-neutralizing, cross-reactive antibodies
were previously shown in vitro to target a conserved epitope in
the HA stalk and were associated with increased infectivity and
virus fusion [17,42]. Cross-reactive, non-neutralizing antibodies
can mediate activation of antibody-dependent cellular cytotoxicity
(ADCC) and the complement cascade [14], that can employ a pro-
tective role on virus clearance [43,44]. Such immune responses
can also lead to excessive production of pro-inflammatory cytoki-
nes and chemokines increasing neutrophil infiltration in IAV
infected pigs resulting in immunopathology, as previously
observed in VAERD affected-pigs [13,45]. MF-59 (similar to NE)
is widely used in influenza vaccines formulations for humans and
was shown to induce a broad antibody response in ferrets [46].
However, both OW groups demonstrated higher homologous titers
and a broader range of HI antibody responses to genetically related
H1 d-lineage strains compared to NE and GP in the antibody land-
scapes. This broader HI antibody response against heterologous
viruses in OW vaccinated pigs suggests an impact on B cell reper-
toire diversity that may also include broader recognition of indi-
vidual HA protein domains or epitopes, including the HA stalk
[17]. Based on findings with the HA, we assessed the range of anti-
body cross-reactivity against the N2 component of the d1-H1N2
vaccine strain using NI assays. Similar to the HI results, both OW
groups induced robust homologous NI titers, as well as cross-
reactive titers to a drifted N2 within the same N2-98 phylogenetic
lineage that were significantly higher than NE or GP, but not
extended to the heterologous N2-02 lineage.
CMI response in IAV infection has been reported to play a role in
virus clearance and reduction in severity of disease [43]. Previous
findings showed that vaccination with WIV-OW elicited homolo-
gous and heterologous specific-IAV responses at 42 dpv without
preventing lung pathology [31], so we assessed the number of
peripheral IFN-c secreting cells as a measurement of T-cell
response. All types of adjuvants in this study activated CMI
responses when stimulated by homologous d1-H1N2 or heterolo-
gous H1N1pdm09, but the CMI responses were not associated with
protection against heterologous challenge (H1N1pdm09), as mea-
sured by lung lesions or virus titers in the nose and lungs. Further-
more, OW groups displayed severe immunopathology in the lungs,
despite the substantial antibody and CMI responses. Future studies
are needed to determine if differential activation of CD4±, CD8±, or
Fig. 5. Spot count (SC) number of antigen-specific IFN-c secreting cells at 28 days post vaccination (dpv) and 42 dpv (pre-challenge) when stimulated with d1-H1N2 (A) and
H1N1pdm09 strain (B). Treatment group means with statistically significant differences (P  0.05) are identified by different lowercase letters.
C.K. Souza et al. / Vaccine 36 (2018) 6103–6110 6109other T-cell subsets contributes to the immunopathologic mecha-
nisms of VAERD.
In conclusion, the type of adjuvant in the WIV formulation
when challenged with a mismatched strain impacted the VAERD
outcome, showing that OW groups had more severe lung pathol-
ogy compared to other adjuvants. However, OW were also associ-
ated with a greater magnitude of HI and NI antibody and CMI
responses and cross-reactivity with heterologous strains within
phylogenetic lineages of HA and NA, indicating a fine line of dis-
tinction between an efficacious adjuvant for WIV and the risk of
immunopathology. Although this study focused on the impact of
adjuvants in the context of VAERD, future vaccine studies should
further evaluate the NE and other adjuvants in influenza vaccines,
but in the full spectrum of breadth of protection from drifted
strains to VAERD, in order to fully understand the extent and lim-
itations of these vaccine components.Acknowledgements
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